Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.47 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15776063 | 0.84 | CYP4F2 (0.52) | CYP4F2CYP4A11GPR119NPC1RAB9A | |
| SCHEMBL15776065 | 0.84 | CYP4F2 (0.52) | CYP4F2CYP4A11GPR119NPC1RAB9A | |
| SCHEMBL4548433 | 0.82 | NPC1 (0.58) | NPC1RAB9ATDP1 | |
| SCHEMBL15776007 | 0.81 | CYP4F2 (0.60) | CYP4F2CYP4A11GPR119PTPRZ1GHSR | |
| SCHEMBL755968 | 0.80 | MAOB (0.56) | CYP4F2CYP4A11 | |
| SCHEMBL227169 | 0.79 | P4HTM (0.58) | RAB9A | |
| SCHEMBL15776310 | 0.78 | CYP4F2 (0.56) | CYP4F2CYP4A11GPR119PTPRZ1GHSR | |
| SCHEMBL14893219 | 0.77 | HTR2A (0.40) | — | |
| SCHEMBL12833592 | 0.77 | CYP4F2 (0.54) | CYP4F2CYP4A11GPR119GHSRMMP13 | |
| SCHEMBL15776018 | 0.75 | CYP4F2 (0.53) | CYP4F2CYP4A11GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290465-B2 | Substituted isoxazole amine compounds as inhibitors of SCD1 | HOFFMANN-LA ROCHE INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | HOFFMANN-LA ROCHE INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2925408-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014086667-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315160-A1 | SUBSTITUTED ISOXAZOLE AMINE COMPOUNDS AS INHIBITORS OF SCD1 | SCD, CPT1A, SCD5 | CYP4F2 446/4885CYP4A11 467/4885GPR119 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.